Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus

Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus

Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a recently identified emerging viral infectious disease. Despite the medical importance of this disease, there are currently neither vaccines nor effective therapeutics for SFTS. T-705, which is a pyrazine derivativ...

Full description

Bibliographic Details
Main Authors: Tani, Hideki, Fukuma, Aiko, Fukushi, Shuetsu, Taniguchi, Satoshi, Yoshikawa, Tomoki, Iwata-Yoshikawa, Naoko, Sato, Yuko, Suzuki, Tadaki, Nagata, Noriyo, Hasegawa, Hideki, Kawai, Yasuhiro, Uda, Akihiko, Morikawa, Shigeru, Shimojima, Masayuki, Watanabe, Haruo, Saijo, Masayuki
Format: Online
Language:English
Published: American Society for Microbiology 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863605/
Description
Summary:Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a recently identified emerging viral infectious disease. Despite the medical importance of this disease, there are currently neither vaccines nor effective therapeutics for SFTS. T-705, which is a pyrazine derivative, has shown broad antiviral activity against various RNA viruses. The present study demonstrated, for the first time to our knowledge, the efficacy of T-705 in treating SFTSV infection in a mouse lethal model. T-705 showed a high efficacy in the treatment of SFTSV infection in the mouse model, even when treatments were initiated after onset of the disease.

Similar Items